Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia
The polycomb protein enhancer of zeste homolog 2 (EZH2) may have a dual role in cancer pathogenesis acting as an oncogene or as a tumor suppressor depending on the cancer type. We recently demonstrated that proteasomal degradation of EZH2 resulting from cyclin-dependent kinase 1 (CDK1)-induced phosp...
Sparad:
| Huvudupphov: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Taylor & Francis Group
2017-03-01
|
| Serie: | Molecular & Cellular Oncology |
| Ämnen: | |
| Länkar: | http://dx.doi.org/10.1080/23723556.2017.1291396 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|